BioCentury | Mar 22, 2018
Politics & Policy

Redfield named CDC director

...heterosexual transmission of the virus and developing the Walter Reed staging system for HIV infection. Mary Romeo Profectus BioSciences Inc. University...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Infectious disease

...has ALVAC-HIV (vCP2438), a canarypox vector-based vaccine, in Phase II/III testing to prevent HIV-1 infection. Profectus BioSciences Inc....
BioCentury | Sep 1, 2016
Company News

Management tracks

...as executive medical director. Lynch also is chairman of Evofem Inc. (San Diego, Calif.) and Profectus BioSciences Inc....
BioCentury | Mar 21, 2016
Company News

Profectus, Vyriad deal

...advanced cancer. The companies will use Vyriad’s recombinant vesicular stomatitis virus (rVSV)-derived oncolytic viruses and Profectus’...
...they expect clinical trials to begin in 2017. The companies declined to disclose financial terms. Profectus BioSciences Inc....
BioCentury | Feb 1, 2016
Clinical News

VesiculoVax-vectored Ebola virus vaccine: Phase I started

...dose-escalation, U.S. Phase I trial to evaluate intramuscular VesiculoVax-vectored Ebola virus vaccine in 39 subjects. Profectus BioSciences Inc....
BioCentury | May 14, 2015
Distillery Therapeutics

Therapeutics: Zaire ebolavirus glycoprotein

...have RVSV-EBOV (rVSV-EBOV; rVSV-ZEBOV-GP ; VSV-EBOV ; VSV-ZEBOV ; BPSC1001 ) in Phase II/III testing. Profectus BioSciences Inc....
BioCentury | Apr 13, 2015
Clinical News

Profectus preclinical data

...In rhesus macaques, a single dose of Profectus’ VesiculoVax Ebola vaccine given 28 days prior to...
...vaccine engineered to express the surface protein from the Zaire variant of the Ebola virus. Profectus BioSciences Inc....
BioCentury | Apr 6, 2015
Company News

BioCryst, U.S. Department of Health and Human Services infectious news

...vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.), NewLink Genetics Corp. (NASDAQ:NLNK, Ames, Iowa) and Profectus BioSciences Inc....
BioCentury | Apr 1, 2015
Company News

HHS awards $12.1M to BioCryst for Ebola treatment

...Diego, Calif.), and Ebola vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), NewLink Genetics Corp. (NASDAQ:NLNK) and Profectus BioSciences Inc....
BioCentury | Mar 19, 2015
Product R&D

AAV for HIV

...formulation of ALVAC HIV vaccine; (D) With assistance from NIAID, the Gates Foundation and MHRP, Profectus Biosciences Inc....
...an antibody response and Ad4-mGag to induce a broadly reactive T cell response Ph I Profectus Biosciences Inc....
...Profectus Biosciences Inc. (D) VesiculoVax HIV vaccine (A) rVSV expressing envelope protein of HIV clade C Preclin Profectus BioSciences Inc....
Items per page:
1 - 10 of 39
BioCentury | Mar 22, 2018
Politics & Policy

Redfield named CDC director

...heterosexual transmission of the virus and developing the Walter Reed staging system for HIV infection. Mary Romeo Profectus BioSciences Inc. University...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Infectious disease

...has ALVAC-HIV (vCP2438), a canarypox vector-based vaccine, in Phase II/III testing to prevent HIV-1 infection. Profectus BioSciences Inc....
BioCentury | Sep 1, 2016
Company News

Management tracks

...as executive medical director. Lynch also is chairman of Evofem Inc. (San Diego, Calif.) and Profectus BioSciences Inc....
BioCentury | Mar 21, 2016
Company News

Profectus, Vyriad deal

...advanced cancer. The companies will use Vyriad’s recombinant vesicular stomatitis virus (rVSV)-derived oncolytic viruses and Profectus’...
...they expect clinical trials to begin in 2017. The companies declined to disclose financial terms. Profectus BioSciences Inc....
BioCentury | Feb 1, 2016
Clinical News

VesiculoVax-vectored Ebola virus vaccine: Phase I started

...dose-escalation, U.S. Phase I trial to evaluate intramuscular VesiculoVax-vectored Ebola virus vaccine in 39 subjects. Profectus BioSciences Inc....
BioCentury | May 14, 2015
Distillery Therapeutics

Therapeutics: Zaire ebolavirus glycoprotein

...have RVSV-EBOV (rVSV-EBOV; rVSV-ZEBOV-GP ; VSV-EBOV ; VSV-ZEBOV ; BPSC1001 ) in Phase II/III testing. Profectus BioSciences Inc....
BioCentury | Apr 13, 2015
Clinical News

Profectus preclinical data

...In rhesus macaques, a single dose of Profectus’ VesiculoVax Ebola vaccine given 28 days prior to...
...vaccine engineered to express the surface protein from the Zaire variant of the Ebola virus. Profectus BioSciences Inc....
BioCentury | Apr 6, 2015
Company News

BioCryst, U.S. Department of Health and Human Services infectious news

...vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.), NewLink Genetics Corp. (NASDAQ:NLNK, Ames, Iowa) and Profectus BioSciences Inc....
BioCentury | Apr 1, 2015
Company News

HHS awards $12.1M to BioCryst for Ebola treatment

...Diego, Calif.), and Ebola vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), NewLink Genetics Corp. (NASDAQ:NLNK) and Profectus BioSciences Inc....
BioCentury | Mar 19, 2015
Product R&D

AAV for HIV

...formulation of ALVAC HIV vaccine; (D) With assistance from NIAID, the Gates Foundation and MHRP, Profectus Biosciences Inc....
...an antibody response and Ad4-mGag to induce a broadly reactive T cell response Ph I Profectus Biosciences Inc....
...Profectus Biosciences Inc. (D) VesiculoVax HIV vaccine (A) rVSV expressing envelope protein of HIV clade C Preclin Profectus BioSciences Inc....
Items per page:
1 - 10 of 39